Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.
Neuroscience Center, Samsung Medical Center, Seoul, Republic of Korea.
Sci Rep. 2019 Jan 24;9(1):564. doi: 10.1038/s41598-018-37252-9.
Mesenchymal stem cells (MSCs) have emerged as one of the promising treatment options for Alzheimer's disease (AD). Although many studies have investigated on the efficacy of MSCs in AD, how MSCs actually change following exposure to the AD environment has not been studied extensively. In this study, we investigated on the potential of AD patient-cerebrospinal fluid (CSF) samples to be used as a formulation of MSCs and its application in AD therapeutics. When Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) were stored in the CSF of AD patients, the stemness of WJ-MSCs was preserved. Furthermore, several genes were upregulated following storage in AD CSF. This signified the therapeutic potential of CSF formulation for AD therapy. Overall, these findings suggest that CSF from AD patients can be an optimal source for MSC formulation.
间充质干细胞（MSCs）已成为治疗阿尔茨海默病（AD）的一种很有前途的治疗方法。尽管许多研究都调查了 MSCs 在 AD 中的疗效，但 MSCs 在暴露于 AD 环境后如何发生变化尚未得到广泛研究。在这项研究中，我们研究了 AD 患者脑脊液（CSF）样本作为 MSCs 配方的潜力及其在 AD 治疗中的应用。当牙髓间充质干细胞（WJ-MSCs）储存在 AD 患者的 CSF 中时，WJ-MSCs 的干性得以保留。此外，在储存于 AD CSF 后，有几个基因上调。这表明 CSF 配方在 AD 治疗中的治疗潜力。总的来说，这些发现表明，AD 患者的 CSF 可以成为 MSC 配方的最佳来源。
